Please assess the completion status of the following clinical trial:

Trial Title: A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of refractory anemia with excess blasts or refractory anemia with excess blasts in transformation according to the French-American-British classification system for myelodysplastic syndromes (MDS) and a relatively high risk of acute myeloid leukemia (AML) transformation, with an International Prognostic Scoring System score of INT-2 or High.~* Be 18 years of age or older~* Have a life expectancy of at least 3 months~* Be unlikely to proceed to bone marrow or stem cell transplantation therapy following remission~* Have serum bilirubin levels less than or equal to 1.5 times the upper limit of normal range for the laboratory~* Have serum glutamic-oxaloacetic transaminase (aspartate aminotransferase) or serum glutamic-pyruvic transaminase (alanine aminotransferase) levels less than or equal to 2 times the upper limit of normal (unless these are considered to be related to transfusion-induced secondary hemosiderosis)~* Have serum creatinine levels less than or equal to 1.5 times the upper limit of normal~Exclusion Criteria:~* Secondary myelodysplastic syndromes (MDS)~* Prior treatment with azacitidine;~* Prior history of acute myeloid leukemia (AML);~* Malignant disease diagnosed within prior 12 months;~* Metastatic disease;~* Hepatic tumors;~* Radiation, chemotherapy, cytotoxic therapy for non-MDS conditions within prior 12 months;~* Prior transplantation or cytotoxic therapy to treat MDS;~* Serious medical illness likely to limit survival to 12 months or less;~* Treatment with erythropoietin or myeloid growth factors during prior 21 days or androgenic hormones during prior 13 days;~* Active HIV, viral hepatitis type B or C;~* Treatment with investigational drugs during prior 30 days;~* Within the 28-day screening period, documented red cell folate deficiency, as evidenced by red blood cell folate (not serum folate) or vitamin B12 deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azacitidine (Type: EXPERIMENTAL): Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
- Conventional Care (Type: ACTIVE_COMPARATOR): Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted

Based on this trial design, predict the completion outcome and termination type (if applicable).